Fda

• The FDA has approved Moderna's mFLUSIVA, the first seasonal influenza vaccine utilizing mRNA technology to receive official authorization. • The vaccine is specifically approved for use in adults aged 50 and older, marking a significant milestone for the drugmaker's mRNA platform. • This approval is critical as it demonstrates the potential for mRNA technology to address broader public health challenges beyond COVID-19.

• The FDA has approved Moderna’s mFlusiva, marking the first time a licensed influenza vaccine has been developed using messenger RNA (mRNA) technology. • This approval represents a significant milestone for mRNA, a platform that gained global prominence during the COVID-19 pandemic but has faced scrutiny from vaccine skeptics. • The shift to mRNA for flu shots is critical because the technology allows for faster production and potentially better matching to evolving seasonal virus strains.

• The FDA has proposed a new hub-and-spoke manufacturing registration rule and approved three new drugs targeting bladder cancer, IgA nephropathy, and multiple myeloma. • A key industry trend highlighted is the shift from intravenous biologics to subcutaneous injectables to reduce patient infusion times and increase clinic capacity. • This transition requires manufacturers to implement complex new fill-finish processes, device-drug combination quality systems, and rigorous safety testing for end-users.

• The FDA is currently reviewing Moderna's mRNA-based flu vaccine, which would be the first of its kind to enter the commercial market. • This decision comes amid a climate of skepticism regarding mRNA technology, highlighted by questions from RFK Jr. and recent HHS funding cuts. • The regulatory uncertainty and funding drops have alarmed venture capital firms, threatening the development of mRNA therapies for Lyme disease and rare cancers.

• An FDA advisory committee has voted in favor of RP1, an experimental melanoma drug developed by Replimune, despite the therapy being rejected in April. • The decision comes during a review meeting where experts evaluated the drug's efficacy and safety for treating melanoma patients. • This endorsement marks a significant reprieve for Replimune, potentially reversing a previous regulatory setback under new FDA leadership.

• An FDA advisory committee is meeting this week to review applications for novel peptide therapies that were previously rejected by former agency officials. • Affiliates of the American Academy of Peptide Medicine allege the FDA ignored critical safety and efficacy data, while industry and consumer advocates warn that approval would bypass traditional drug regulations. • Separately, the FDA’s oncology center released three final guidance documents on Monday designed to expand patient access to cancer clinical trials.

• The FDA has raised concerns regarding the efficacy of Capricor Therapeutics' treatment for Duchenne muscular dystrophy ahead of an upcoming advisory committee hearing. • The agency's skepticism contradicts claims made by Capricor regarding the clinical benefits of the rare disease drug. • This development is critical as it may influence the FDA's final decision on whether to grant regulatory approval for the therapy.